AlveoGene
Latest round
- Seed
Last raised
- Jul 2023
Total raised
- $2.2M
Investors
- 3
About AlveoGene
Based in Oxford, UK, and founded in 2022, AlveoGene operates as a biotechnology research firm focused on finding remedies for rare respiratory diseases using inhaled gene therapy. The company offers treatment for the rare respiratory diseases. With the exception of using the CFTR gene, which is mutated in cystic fibrosis, it retains the exclusive license to a proprietary and validated next-generation lentiviral delivery platform created by the GTC for the treatment of respiratory disorders with high unmet needs.
Who invested in AlveoGene
3 investors across 1 round
See all investors in AlveoGene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jul 24, 2023
Amount
$2.2M
Investors
Questions about AlveoGene
Who invested in AlveoGene?
AlveoGene has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AlveoGene raised?
AlveoGene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AlveoGene last raise money?
AlveoGene's most recent round on record is a Seed, in Jul 2023.
What does AlveoGene do?
Based in Oxford, UK, and founded in 2022, AlveoGene operates as a biotechnology research firm focused on finding remedies for rare respiratory diseases using inhaled gene therapy.
Where is AlveoGene headquartered?
AlveoGene is headquartered in Oxford, UK.
Which VCs invest in companies like AlveoGene?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at AlveoGene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like AlveoGene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.